Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia.

[1]  C. Récher,et al.  Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies , 2018, Leukemia & lymphoma.

[2]  G. Marcucci,et al.  Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia , 2018, Haematologica.

[3]  M. Konopleva,et al.  Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000 , 2018, Cancer.

[4]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[5]  M. Konopleva,et al.  Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.

[6]  J. Griffin,et al.  Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy , 2017, OncoTargets and therapy.

[7]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[8]  J. Passweg,et al.  Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML) , 2017, Leukemia and Lymphoma.

[9]  M. Wetzler,et al.  Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. , 2015, Clinical lymphoma, myeloma & leukemia.

[10]  F. Ravandi.  Relapsed acute myeloid leukemia: why is there no standard of care? , 2013, Best practice & research. Clinical haematology.

[11]  Jorge Cortes,et al.  Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. , 2013, Blood.

[12]  E. Estey,et al.  Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia , 2011, British journal of haematology.

[13]  J. Klein,et al.  Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Thall,et al.  Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  R. Bouabdallah,et al.  High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group , 2007, Leukemia.

[16]  H. Kantarjian,et al.  Outcome of patients with acute myelogenous leukemia after second salvage therapy , 2005, Cancer.

[17]  Bob Löwenberg,et al.  Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  U. Creutzig,et al.  Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Horowitz,et al.  An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation , 1997, Current opinion in hematology.